Vaccines to Prevent High-Grade Glioma

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

In this video, Hideho Okada, MD, PhD, of the University of California, San Francisco, discusses current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

Okada gave a presentation on this topic at the 2017 American Association for Cancer Researcher (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Related Content
Guideline Update Supports Laser Therapy for Brain Tumors After SRS

Guideline Update Supports Laser Therapy for Brain Tumors After SRS

Tim Cortese
April 2nd 2025
Article

The REMASTer trial found that laser interstitial thermal therapy was equivalent to open craniotomy regarding OS and PFS data in progressive metastatic brain tumors.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Promising Trials May Have an Impact in the Brain Tumor Environment

Promising Trials May Have an Impact in the Brain Tumor Environment

Tim Cortese
February 17th 2025
Article

Frances Chow, MD, and Elizabeth Ren Zhang-Velten, MD, PhD, spoke about several facets of the current brain tumor landscape, including targeted therapies.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.

Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies

Russ Conroy
January 17th 2025
Article

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

FDA Receives NDA for Dordaviprone in Recurrent H3 K27M+ Glioma

Russ Conroy
January 2nd 2025
Article

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.